0
2022
Hepatitis E Diagnostic Tests Market

Hepatitis E Diagnostic Tests Market

by Test Type (ELISA HEV IgM Test, ELISA HEV IgG Test, RT-PCR Test), by End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Report Code: A15447
Oct 2022 | Pages: 171
Tables: 115
Charts: 55
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Hepatitis E Diagnostic Tests Market Research, 2031

The global hepatitis E diagnostic tests market size was valued at $61.7 million in 2021, and is projected to reach $93.5 million by 2031, growing at a CAGR of 4.2% from 2022 to 2031. Hepatitis E is a liver disease caused due to infection of hepatitis E virus (HEV). It includes inflammation to the liver along with some symptoms such as jaundice and nausea. The infection is usually transmitted through oral-fecal route, where drinking water contaminated with fecal residues remains the main cause of infection. In addition, vertical transmission that is from pregnant women to the baby, infected blood products used in medical treatments and intake of uncooked meat and meat products from hepatitis E infected animals are the major factors for the spread of infection.

The COVID-19 outbreak is anticipated to have a negative impact on growth of the global hepatitis E diagnostic tests market. A survey was carried out by the World Hepatitis Alliance (WHA), a network of more than 300 community-based organizations across 100 countries in March–April, 2020. According to the survey, there was interruptions in the services, along with delays in implementing major programs regarding the hepatitis diagnosis and management. Moreover, the COVID-19 pandemic has affected the hepatitis prevention, testing, treatment, and vaccination services around the globe, which further lead to a negative impact on the hepatitis E diagnostic test market.

Hepatitis E Diagnostic Tests Market

Furthermore, hepatitis E presents is a hyper endemic disease in low-resource countries where there is poor sanitation which leads to fecal contamination of food and water supplies. Inappropriate sanitation in the underdeveloped and developing countries is also the main cause of this infection and these regions are the main targets for spread of diseases such as hepatitis E and others. This leads to rise in number of hepatitis infection cases, which further rises the demand for hepatitis E diagnostic test kits in this region.

Furthermore, hepatitis E can also lead to serious health threats to patients with pre-existing chronic liver disease and organ-transplant recipients on immunosuppressive therapy, which results in severe liver disease and death of the patient. In addition, during epidemics, fulminant hepatitis E is witnessed on a large scale among pregnant women, which is typically most severe during the third trimester of pregnancy. According to World Health Organization, 20–25% of pregnant women are at high risk and may die if infected by hepatitis E in third trimester. This highlights the need for early diagnosis of this infection which rises the demand for hepatitis E diagnostic tests kits, and propels the growth of the hepatitis E diagnostic tests market size.

In addition, rise in prevalence of hepatitis E, rise in awareness about hepatitis E and its diagnosis among people, and rise R&D activities in the diagnostic field are the driving factors for the hepatitis E diagnostic tests market share. These drivers provide a favorable environments for increase in  the sales of the products and also for the growth of the overall market. However, the market may be somewhat constrained throughout the anticipated period due to complications in handling the kits and limitation in its storage conditions.

Impact of COVID-19 Hepatitis E Diagnostic Tests Market

Coronavirus Severe acute respiration syndrome (SARS-CoV-2) is an infectious disease caused by the novel coronavirus (COVID-19), which originated in the Wuhan district in China in the late 2019, and since has spread to 212 countries. WHO declared COVID-19 as a pandemic on March 11, 2020, and by September 21, 2022, over 613 million people have been infected globally with over 65.3 lakhs deaths. COVID-19 symptoms include fever, cough, and shortness of breath.

The COVID-19 outbreak is anticipated to have a negative impact on growth of the global hepatitis E diagnostic tests market. A survey was carried out by the World Hepatitis Alliance (WHA), a network of more than 300 community-based organizations across 100 countries in March–April, 2020. According to the survey, there was interruptions in the services, along with delays in implementing major programs regarding the hepatitis diagnosis and management. Moreover, the COVID-19 pandemic has affected the hepatitis prevention, testing, treatment, and vaccination services around the globe, which further lead to a negative impact on the hepatitis E diagnostic test market.

In addition, the COVID-19 have also imperiled the national elimination plan for viral hepatitis owing to diverted resources and attention of the healthcare sector. Furthermore, the government funding in hepatitis cases reduced due to COVID- 19 funding, which further reduced the patients opting for diagnosis and treatment of hepatitis E. In addition, decrease in the patient visit to the hospitals reduced during the pandemic, which further negatively affected the hepatitis E diagnostic tests market growth.

However, regularization of supply chain of medications and medical devices by key players and rise in the number of patient visits for investigation and treatment post pandemic is anticipated to fuel the growth of market after COVID-19 pandemic.

The hepatitis E diagnostic tests market is segmented on the basis of test type, by end user and region. On the basis of test type, it is divided into ELISA HEV IgM test, ELISA HEV IgG test, and RT-PCR test. On the basis of end user, the market is segmented into hospitals, diagnostic centers, and others.

On the basis of, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

On the basis of test type, the HEV IgM ELISA Test segment registered the largest revenue for the year 2021, and is expected to grow at a highest CAGR during the hepatitis E diagnostic tests market forecast period owing to the rise in the investment by the key market players to manufacture the HEV IgM ELISA Test and others associated products to meet the rising demand of the healthcare sector.

Hepatitis E Diagnostic Tests Market

On the basis of end user, the diagnostic centers segment held the largest share of the hepatitis E diagnostic tests market in 2021 and is expected to grow at the highest CAGR during the forecast period, which is mainly rise in number of diagnostic centers around the globe due to the rise in demand for diagnostic services during the COVID-19 pandemic.

Hepatitis E Diagnostic Tests Market

On the basis of region, Asia-Pacific acquired a major share in 2021, and is expected to witness the highest rate of CAGR for the hepatitis E diagnostic tests market during the forecast period owing to prevalence of various infectious diseases in this region. This, leads to rise in sale of diagnostic kits and increase the revenue share of this region.

Hepatitis E Diagnostic Tests Market

Some of the major companies that operate in the global hepatitis E diagnostic tests industry are  Altona Diagnostics GmbH,  Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd,  Dia.Pro Diagnostic Bioprobes s.r.l, ELITechGroup, F. Hoffmann-La Roche Ltd., Fortress Diagnostics, Mikrogen Diagnostik, MP Biomedicals, PerkinElmer, Inc.  (EUROIMMUN Medizinische Labordiagnostika AG) and Primerdesign Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hepatitis e diagnostic tests market analysis from 2021 to 2031 to identify the prevailing hepatitis e diagnostic tests market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the hepatitis e diagnostic tests market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global hepatitis e diagnostic tests market trends, key players, market segments, application areas, and market growth strategies.

Hepatitis E Diagnostic Tests Market Report Highlights

Aspects Details
Market Size By 2031 USD 93.5 million
Growth Rate CAGR of 4.2%
Forecast period 2021 - 2031
Report Pages 171
By Test Type
  • ELISA HEV IgM Test
  • ELISA HEV IgG Test
  • RT-PCR Test
By End User
  • Hospitals
  • Diagnostic Centers
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players PerkinElmer, Inc, Dia.Pro - Diagnostic Bioprobes s.r.l, ELITechGroup, Mikrogen GmbH, Beijing Wantai Biolog Pha Ent Co Ltd, Altona Diagnostics, MP Biomedicals LLP, Fortress Diagnostics, F. Hoffmann-La Roche Ltd., Primerdesign Ltd
 
  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 ELISA HEV IgM Test

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market share analysis by country

    • 4.3 ELISA HEV IgG Test

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market share analysis by country

    • 4.4 RT-PCR Test

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market share analysis by country

  • CHAPTER 5: HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Hospitals

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market share analysis by country

    • 5.3 Diagnostic Centers

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market share analysis by country

    • 5.4 Others

      • 5.4.1 Key market trends, growth factors and opportunities

      • 5.4.2 Market size and forecast, by region

      • 5.4.3 Market share analysis by country

  • CHAPTER 6: HEPATITIS E DIAGNOSTIC TESTS MARKET, BY REGION

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 North America

      • 6.2.1 Key trends and opportunities

      • 6.2.2 North America Market size and forecast, by Test Type

      • 6.2.3 North America Market size and forecast, by End User

      • 6.2.4 North America Market size and forecast, by country

        • 6.2.4.1 U.S.
          • 6.2.4.1.1 Key market trends, growth factors and opportunities
          • 6.2.4.1.2 Market size and forecast, by Test Type
          • 6.2.4.1.3 Market size and forecast, by End User
        • 6.2.4.2 Canada
          • 6.2.4.2.1 Key market trends, growth factors and opportunities
          • 6.2.4.2.2 Market size and forecast, by Test Type
          • 6.2.4.2.3 Market size and forecast, by End User
        • 6.2.4.3 Mexico
          • 6.2.4.3.1 Key market trends, growth factors and opportunities
          • 6.2.4.3.2 Market size and forecast, by Test Type
          • 6.2.4.3.3 Market size and forecast, by End User
    • 6.3 Europe

      • 6.3.1 Key trends and opportunities

      • 6.3.2 Europe Market size and forecast, by Test Type

      • 6.3.3 Europe Market size and forecast, by End User

      • 6.3.4 Europe Market size and forecast, by country

        • 6.3.4.1 Germany
          • 6.3.4.1.1 Key market trends, growth factors and opportunities
          • 6.3.4.1.2 Market size and forecast, by Test Type
          • 6.3.4.1.3 Market size and forecast, by End User
        • 6.3.4.2 France
          • 6.3.4.2.1 Key market trends, growth factors and opportunities
          • 6.3.4.2.2 Market size and forecast, by Test Type
          • 6.3.4.2.3 Market size and forecast, by End User
        • 6.3.4.3 UK
          • 6.3.4.3.1 Key market trends, growth factors and opportunities
          • 6.3.4.3.2 Market size and forecast, by Test Type
          • 6.3.4.3.3 Market size and forecast, by End User
        • 6.3.4.4 Italy
          • 6.3.4.4.1 Key market trends, growth factors and opportunities
          • 6.3.4.4.2 Market size and forecast, by Test Type
          • 6.3.4.4.3 Market size and forecast, by End User
        • 6.3.4.5 Spain
          • 6.3.4.5.1 Key market trends, growth factors and opportunities
          • 6.3.4.5.2 Market size and forecast, by Test Type
          • 6.3.4.5.3 Market size and forecast, by End User
        • 6.3.4.6 Rest of Europe
          • 6.3.4.6.1 Key market trends, growth factors and opportunities
          • 6.3.4.6.2 Market size and forecast, by Test Type
          • 6.3.4.6.3 Market size and forecast, by End User
    • 6.4 Asia-Pacific

      • 6.4.1 Key trends and opportunities

      • 6.4.2 Asia-Pacific Market size and forecast, by Test Type

      • 6.4.3 Asia-Pacific Market size and forecast, by End User

      • 6.4.4 Asia-Pacific Market size and forecast, by country

        • 6.4.4.1 Japan
          • 6.4.4.1.1 Key market trends, growth factors and opportunities
          • 6.4.4.1.2 Market size and forecast, by Test Type
          • 6.4.4.1.3 Market size and forecast, by End User
        • 6.4.4.2 China
          • 6.4.4.2.1 Key market trends, growth factors and opportunities
          • 6.4.4.2.2 Market size and forecast, by Test Type
          • 6.4.4.2.3 Market size and forecast, by End User
        • 6.4.4.3 Australia
          • 6.4.4.3.1 Key market trends, growth factors and opportunities
          • 6.4.4.3.2 Market size and forecast, by Test Type
          • 6.4.4.3.3 Market size and forecast, by End User
        • 6.4.4.4 India
          • 6.4.4.4.1 Key market trends, growth factors and opportunities
          • 6.4.4.4.2 Market size and forecast, by Test Type
          • 6.4.4.4.3 Market size and forecast, by End User
        • 6.4.4.5 South Korea
          • 6.4.4.5.1 Key market trends, growth factors and opportunities
          • 6.4.4.5.2 Market size and forecast, by Test Type
          • 6.4.4.5.3 Market size and forecast, by End User
        • 6.4.4.6 Rest of Asia-Pacific
          • 6.4.4.6.1 Key market trends, growth factors and opportunities
          • 6.4.4.6.2 Market size and forecast, by Test Type
          • 6.4.4.6.3 Market size and forecast, by End User
    • 6.5 LAMEA

      • 6.5.1 Key trends and opportunities

      • 6.5.2 LAMEA Market size and forecast, by Test Type

      • 6.5.3 LAMEA Market size and forecast, by End User

      • 6.5.4 LAMEA Market size and forecast, by country

        • 6.5.4.1 Brazil
          • 6.5.4.1.1 Key market trends, growth factors and opportunities
          • 6.5.4.1.2 Market size and forecast, by Test Type
          • 6.5.4.1.3 Market size and forecast, by End User
        • 6.5.4.2 Saudi Arabia
          • 6.5.4.2.1 Key market trends, growth factors and opportunities
          • 6.5.4.2.2 Market size and forecast, by Test Type
          • 6.5.4.2.3 Market size and forecast, by End User
        • 6.5.4.3 South Africa
          • 6.5.4.3.1 Key market trends, growth factors and opportunities
          • 6.5.4.3.2 Market size and forecast, by Test Type
          • 6.5.4.3.3 Market size and forecast, by End User
        • 6.5.4.4 Rest of LAMEA
          • 6.5.4.4.1 Key market trends, growth factors and opportunities
          • 6.5.4.4.2 Market size and forecast, by Test Type
          • 6.5.4.4.3 Market size and forecast, by End User
  • CHAPTER 7: COMPANY LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top winning strategies

    • 7.3. Product Mapping of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Key developments

  • CHAPTER 8: COMPANY PROFILES

    • 8.1 MP Biomedicals LLP

      • 8.1.1 Company overview

      • 8.1.2 Company snapshot

      • 8.1.3 Operating business segments

      • 8.1.4 Product portfolio

      • 8.1.5 Business performance

      • 8.1.6 Key strategic moves and developments

    • 8.2 F. Hoffmann-La Roche Ltd.

      • 8.2.1 Company overview

      • 8.2.2 Company snapshot

      • 8.2.3 Operating business segments

      • 8.2.4 Product portfolio

      • 8.2.5 Business performance

      • 8.2.6 Key strategic moves and developments

    • 8.3 Altona Diagnostics

      • 8.3.1 Company overview

      • 8.3.2 Company snapshot

      • 8.3.3 Operating business segments

      • 8.3.4 Product portfolio

      • 8.3.5 Business performance

      • 8.3.6 Key strategic moves and developments

    • 8.4 PerkinElmer, Inc

      • 8.4.1 Company overview

      • 8.4.2 Company snapshot

      • 8.4.3 Operating business segments

      • 8.4.4 Product portfolio

      • 8.4.5 Business performance

      • 8.4.6 Key strategic moves and developments

    • 8.5 Dia.Pro - Diagnostic Bioprobes s.r.l

      • 8.5.1 Company overview

      • 8.5.2 Company snapshot

      • 8.5.3 Operating business segments

      • 8.5.4 Product portfolio

      • 8.5.5 Business performance

      • 8.5.6 Key strategic moves and developments

    • 8.6 Beijing Wantai Biolog Pha Ent Co Ltd

      • 8.6.1 Company overview

      • 8.6.2 Company snapshot

      • 8.6.3 Operating business segments

      • 8.6.4 Product portfolio

      • 8.6.5 Business performance

      • 8.6.6 Key strategic moves and developments

    • 8.7 ELITechGroup

      • 8.7.1 Company overview

      • 8.7.2 Company snapshot

      • 8.7.3 Operating business segments

      • 8.7.4 Product portfolio

      • 8.7.5 Business performance

      • 8.7.6 Key strategic moves and developments

    • 8.8 Fortress Diagnostics

      • 8.8.1 Company overview

      • 8.8.2 Company snapshot

      • 8.8.3 Operating business segments

      • 8.8.4 Product portfolio

      • 8.8.5 Business performance

      • 8.8.6 Key strategic moves and developments

    • 8.9 Mikrogen GmbH

      • 8.9.1 Company overview

      • 8.9.2 Company snapshot

      • 8.9.3 Operating business segments

      • 8.9.4 Product portfolio

      • 8.9.5 Business performance

      • 8.9.6 Key strategic moves and developments

    • 8.10 Primerdesign Ltd

      • 8.10.1 Company overview

      • 8.10.2 Company snapshot

      • 8.10.3 Operating business segments

      • 8.10.4 Product portfolio

      • 8.10.5 Business performance

      • 8.10.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 2. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR ELISA HEV IGM TEST, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 3. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR ELISA HEV IGM TEST, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 4. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR ELISA HEV IGG TEST, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 5. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR ELISA HEV IGG TEST, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 6. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR RT-PCR TEST, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 7. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR RT-PCR TEST, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 8. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 9. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 10. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 11. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 12. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 13. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 14. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 15. HEPATITIS E DIAGNOSTIC TESTS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 16. NORTH AMERICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 17. NORTH AMERICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 18. NORTH AMERICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 19. U.S. HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 20. U.S. HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 21. CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 22. CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 23. MEXICO HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 24. MEXICO HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 25. EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 26. EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 27. EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 28. GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 29. GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 30. FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 31. FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 32. UK HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 33. UK HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 34. ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 35. ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 36. SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 37. SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 38. REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 39. REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 40. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 41. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 42. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 43. JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 44. JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 45. CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 46. CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 47. AUSTRALIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 48. AUSTRALIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 49. INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 50. INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 51. SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 52. SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 53. REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 54. REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 55. LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 56. LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 57. LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 58. BRAZIL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 59. BRAZIL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 60. SAUDI ARABIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 61. SAUDI ARABIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 62. SOUTH AFRICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 63. SOUTH AFRICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 64. REST OF LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 65. REST OF LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
    TABLE 66.MP BIOMEDICALS LLP: COMPANY SNAPSHOT
    TABLE 67.MP BIOMEDICALS LLP: OPERATING SEGMENTS
    TABLE 68.MP BIOMEDICALS LLP: PRODUCT PORTFOLIO
    TABLE 69.MP BIOMEDICALS LLP: NET SALES
    TABLE 70.MP BIOMEDICALS LLP: KEY STRATERGIES
    TABLE 71.F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
    TABLE 72.F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
    TABLE 73.F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
    TABLE 74.F. HOFFMANN-LA ROCHE LTD.: NET SALES
    TABLE 75.F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
    TABLE 76.ALTONA DIAGNOSTICS: COMPANY SNAPSHOT
    TABLE 77.ALTONA DIAGNOSTICS: OPERATING SEGMENTS
    TABLE 78.ALTONA DIAGNOSTICS: PRODUCT PORTFOLIO
    TABLE 79.ALTONA DIAGNOSTICS: NET SALES
    TABLE 80.ALTONA DIAGNOSTICS: KEY STRATERGIES
    TABLE 81.PERKINELMER, INC: COMPANY SNAPSHOT
    TABLE 82.PERKINELMER, INC: OPERATING SEGMENTS
    TABLE 83.PERKINELMER, INC: PRODUCT PORTFOLIO
    TABLE 84.PERKINELMER, INC: NET SALES
    TABLE 85.PERKINELMER, INC: KEY STRATERGIES
    TABLE 86.DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: COMPANY SNAPSHOT
    TABLE 87.DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: OPERATING SEGMENTS
    TABLE 88.DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: PRODUCT PORTFOLIO
    TABLE 89.DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: NET SALES
    TABLE 90.DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: KEY STRATERGIES
    TABLE 91.BEIJING WANTAI BIOLOG PHA ENT CO LTD: COMPANY SNAPSHOT
    TABLE 92.BEIJING WANTAI BIOLOG PHA ENT CO LTD: OPERATING SEGMENTS
    TABLE 93.BEIJING WANTAI BIOLOG PHA ENT CO LTD: PRODUCT PORTFOLIO
    TABLE 94.BEIJING WANTAI BIOLOG PHA ENT CO LTD: NET SALES
    TABLE 95.BEIJING WANTAI BIOLOG PHA ENT CO LTD: KEY STRATERGIES
    TABLE 96.ELITECHGROUP: COMPANY SNAPSHOT
    TABLE 97.ELITECHGROUP: OPERATING SEGMENTS
    TABLE 98.ELITECHGROUP: PRODUCT PORTFOLIO
    TABLE 99.ELITECHGROUP: NET SALES
    TABLE 100.ELITECHGROUP: KEY STRATERGIES
    TABLE 101.FORTRESS DIAGNOSTICS: COMPANY SNAPSHOT
    TABLE 102.FORTRESS DIAGNOSTICS: OPERATING SEGMENTS
    TABLE 103.FORTRESS DIAGNOSTICS: PRODUCT PORTFOLIO
    TABLE 104.FORTRESS DIAGNOSTICS: NET SALES
    TABLE 105.FORTRESS DIAGNOSTICS: KEY STRATERGIES
    TABLE 106.MIKROGEN GMBH: COMPANY SNAPSHOT
    TABLE 107.MIKROGEN GMBH: OPERATING SEGMENTS
    TABLE 108.MIKROGEN GMBH: PRODUCT PORTFOLIO
    TABLE 109.MIKROGEN GMBH: NET SALES
    TABLE 110.MIKROGEN GMBH: KEY STRATERGIES
    TABLE 111.PRIMERDESIGN LTD: COMPANY SNAPSHOT
    TABLE 112.PRIMERDESIGN LTD: OPERATING SEGMENTS
    TABLE 113.PRIMERDESIGN LTD: PRODUCT PORTFOLIO
    TABLE 114.PRIMERDESIGN LTD: NET SALES
    TABLE 115.PRIMERDESIGN LTD: KEY STRATERGIES
  • LIST OF FIGURES

  • FIGURE 1.HEPATITIS E DIAGNOSTIC TESTS MARKET SEGMENTATION
    FIGURE 2.HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031
    FIGURE 3.HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.HEPATITIS E DIAGNOSTIC TESTS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.HEPATITIS E DIAGNOSTIC TESTS MARKET,BY TEST TYPE,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ELISA HEV IGM TEST HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ELISA HEV IGG TEST HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF RT-PCR TEST HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031(%)
    FIGURE 16.HEPATITIS E DIAGNOSTIC TESTS MARKET,BY END USER,2021(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HOSPITALS HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC CENTERS HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF OTHERS HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031(%)
    FIGURE 20.HEPATITIS E DIAGNOSTIC TESTS MARKET BY REGION,2021
    FIGURE 21.U.S. HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 22.CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 23.MEXICO HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 24.GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 25.FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 26.UK HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 27.ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 28.SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 29.REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 30.JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 31.CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 32.AUSTRALIA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 33.INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 34.SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 35.REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 36.BRAZIL HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 37.SAUDI ARABIA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 38.SOUTH AFRICA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 39.REST OF LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
    FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 43.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 44.COMPETITIVE DASHBOARD
    FIGURE 45.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 46.MP BIOMEDICALS LLP.: NET SALES ($MILLION)
    FIGURE 47.F. HOFFMANN-LA ROCHE LTD..: NET SALES ($MILLION)
    FIGURE 48.ALTONA DIAGNOSTICS.: NET SALES ($MILLION)
    FIGURE 49.PERKINELMER, INC.: NET SALES ($MILLION)
    FIGURE 50.DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L.: NET SALES ($MILLION)
    FIGURE 51.BEIJING WANTAI BIOLOG PHA ENT CO LTD.: NET SALES ($MILLION)
    FIGURE 52.ELITECHGROUP.: NET SALES ($MILLION)
    FIGURE 53.FORTRESS DIAGNOSTICS.: NET SALES ($MILLION)
    FIGURE 54.MIKROGEN GMBH.: NET SALES ($MILLION)
    FIGURE 55.PRIMERDESIGN LTD.: NET SALES ($MILLION)

 
 

This section provides the opinions of the top-level CXOs operating in the global hepatitis E diagnostic tests market. According to the insights of the CXOs, the global hepatitis E diagnostic tests market is expected to exhibit high growth potential attributable to factor such as rise in in R&D activities in pharmaceutical industry for manufacturing of the diagnostic kits. In addition, increase in prevalence of hepatitis E cases and chronic hepatitis and surge in number advancements in the diagnosis and treatment are driving the market growth. Furthermore, the hepatitis E diagnostic tests market has gained interest of many pharmaceutical companies, owing to surge in demand for the diagnostic kits due to rise in the patient pool in the regions such as Asia-Pacific and LAMEA. Moreover, increase in number of geriatric patients, who are highly prone to viral and bacterial infections due to poor immunity, notably contributes toward the growth of the hepatitis E diagnostic tests market.

In addition, hepatitis E infection occurs around the world both as outbreaks and as sporadic cases. Outbreaks are mainly witnessed in countries with limited access to essential water, sanitation, hygiene and health services, which affects more than thousands of people in that region. However, government and non-government organizations here mainly focus on creating awareness about this condition and also provide funds for the prevention, diagnosis and treatment of hepatitis E infection.

The CXOs further added that Asia-Pacific is expected to witness the highest growth, in terms of revenue, owing to the presence of key players, rise in government initiatives, development in healthcare infrastructure, rise in prevalence of health issues, and is expected to register highest growth during the forecast period

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. Rise in prevalence of hepatitis E, rise in awareness about hepatitis E and its diagnosis among people, and rise R&D activities in the diagnostic field are the upcoming trends of Hepatitis E Diagnostic Tests Market in the world

A. Lever infection is the leading application of Hepatitis E Diagnostic Tests Market

A. Asia-Pacific is the largest regional market for Hepatitis E Diagnostic Tests.

A. Hepatitis E Diagnostic Tests is projected to reach $93.5 million by 2031, registering a CAGR of 4.2% from 2022 to 2031.

A. Some of the major companies that operate in the global Hepatitis E diagnostic tests market are Altona Diagnostics GmbH, Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd, Dia.Pro Diagnostic Bioprobes s.r.l, ELITechGroup, F. Hoffmann-La Roche Ltd., Fortress Diagnostics, Mikrogen Diagnostik, MP Biomedicals, PerkinElmer, Inc. (EUROIMMUN Medizinische Labordiagnostika AG) and Primerdesign Ltd.

A. The base year is 2021 in Hepatitis E Diagnostic Tests market

A. Yes, the Hepatitis E Diagnostic Tests market report provides PORTER Analysis

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Hepatitis E Diagnostic Tests Market

Start reading instantly.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers